Botulinum neurotoxin type A in facial aesthetics

Bibliography

• CARRUTHERS JD, CARRUTHERS JA: Treatment of glabellar frown lines with C. Botulinum-A exotoxin. J. Dermatol. Surg. Oncol. (1992) 18(1):17-21.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS J, FAGIEN S, MATARASSO SL; AND THE BOTOX CONSENSUS GROUP: Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast. Reconstr. Surg. (2004) 114(6 Suppl.):1S-22S.
   PubMed Web of Science ®Google Scholar
• FORAN PG, MOHAMMED N, LISK GO et al.: Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exoctyosis in central neurons. J. Biol. Chem. (2003) 278(2):1363-1371.
   PubMed Web of Science ®Google Scholar
• MEZAKI T, KAJI R, KOHARA N et al.: Comparison of therapeutic efficacies of type A and type F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology (1995) 45(3 Pt 1):506-508.
   PubMed Web of Science ®Google Scholar
• DOLLY JO, AOKI KR: The structure and mode of action of different botulinum toxins. Eur. J. Neurol. (2006) 13(Suppl. 4):1-9.
   PubMed Web of Science ®Google Scholar
• INOUE K, FUJINAGA Y, WATANABE T et al.: Molecular composition of Clostridium botulinum type A progenitor toxins. Infect. Immun. (1996) 64(5):1589-1594.
   PubMed Web of Science ®Google Scholar
• AURORA S: Botulinum toxin type A for the treatment of migraine. Expert Opin. Pharmacother. (2006) 7(8):1085-1095.
   PubMed Web of Science ®Google Scholar
• FOSTER KA, BIGALKE H, AOKI KR: Botulinum neurotoxin – from laboratory to bedside. Neurotox. Res. (2006) 9(2-3):133-140.
   PubMed Web of Science ®Google Scholar
• AOKI KR, RANOUX D, WISSEL J: Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur. J. Neurol. (2006) 13(Suppl. 4):10-19.
   PubMed Web of Science ®Google Scholar
• DONG M, YEH F, TEPP WH et al.: SV2 is the protein receptor for botulinum neurotoxin A. Science (2006) 312(5773):592-596.
   PubMed Web of Science ®Google Scholar
• JIN R, RUMMEL A, BINZ T, BRUNGER AT: Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature (2006) 444(7122):1092-1095.
   PubMed Web of Science ®Google Scholar
• ALLERGAN, INC.: BOTOX® (Botulinum Toxin type A) prescribing information. Allergan, Inc., Irvine (CA) USA (2005).
   Google Scholar
• IPSEN LTD: Dysport® (Botulinum Toxin type A) prescribing information. Ipsen Ltd, Slough, Berkshire, UK (2004).
   Google Scholar
• SOLSTICE NEUROSCIENCES, INC.: Myobloc® (Botulinum Toxin type B) prescribing information. Solstice Neurosciences, Inc., South San Francisco (CA) USA (2004).
   Google Scholar
• SCHANTZ EJ, JOHNSON EA: Preparation and characterization of botulinum toxin type A for human treatment. In: Therapy with Botulinum Toxin. Jankovic J, Hallet M (Eds). Marcel Dekker, Inc., New York, USA (1994):41-49.
   Google Scholar
• MARKEY AC. Dysport. Dermatol. Clin. (2004) 22(2):213-219.
   PubMed Web of Science ®Google Scholar
• HAMBLETON P, CAPEL B, BAILEY N et al.: Production, purification and toxoiding of Clostridium botulinum type A toxin. In: Biomedical Aspects of Botulism. Angel PS, Lewis GE (Eds). Academic Press, Inc., New York, USA (1981):247-260.
   Google Scholar
• HIRTZER P, CHUNG J, DIAS B, KANNAN K, PATEL N, CALLAWAY J: Complex integrity of botulinum toxin type B (NeuroBloc™): implications for the incidence of secondary non-responders. Eur. J. Neurol. (2001) 8(Suppl. 4):25.
   Google Scholar
• PEARCE LB, FIRST ER, MACCALLUM RD, GUPTA A: Pharmacologic characterization of botulinum toxin for basic science and medicine. Toxicon (1997) 35(9):1373-1412.
   PubMed Web of Science ®Google Scholar
• SCHANTZ EJ, JOHNSON EA: Dose standardisation of botulinum toxin. Lancet (1990) 335(8686):421.
   PubMedGoogle Scholar
• SAMPAIO C, COSTA J, FERREIRA JJ: Clinical comparability of marketed formulations of botulinum toxin. Mov. Disord. (2004) 19(Suppl. 8):S129-S136.
   PubMed Web of Science ®Google Scholar
• HAMILTON MT, HOLCK DE, MARSHALL S et al.: Comparison of high-dose botulinum toxin type B to botulinum toxin type A in the amelioration of lateral canthal wrinkles. Invest. Ophthalmol. Vis. Sci. (2004) 29:ARVO E-Abstract B2.
   Google Scholar
• MATARASSO SL: Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol. Surg. (2003) 29(1):7-13.
   PubMed Web of Science ®Google Scholar
• LOWE NJ, YAMAUCHI PS, LASK GP, PATNAIK R, MOORE D: Botulinum toxin types A and B for brow furrows: preliminary experiences with type B toxin dosing. J. Cosmet. Laser Ther. (2002) 4(1):15-18.
   PubMedGoogle Scholar
• FLYNN TC, CLARK RE II: Botulinum toxin type B (MYOBLOC) versus botulinum type A (BOTOX) frontalis study; rate of onset and radius of diffusion. Dermatol. Surg. (2003) 29(5):519-522.
   PubMed Web of Science ®Google Scholar
• ALSTER TS, LUPTON JR: Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol. Surg. (2003) 29(5):516-518.
   PubMed Web of Science ®Google Scholar
• LOWE P, PATNAIK R, LOWE N: Comparison of 2 formulations of botulinum type A toxin for the treatment of glabellar lines: a double-blind, randomized study. J. Amer. Acad. Dermatol. (2006) 55:975-980.
   PubMed Web of Science ®Google Scholar
• NÜSSGENS Z, ROGGENKÄMPER P: Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch. Clin. Exp. Ophthalmol. (1997) 235(4):197-199.
   PubMed Web of Science ®Google Scholar
• SMUTS JA, DE BOULLE K, VAN COLLER R, BARNARD PW: An electrophysiological study to demonstrate in vivo differences between two types of botulinum toxin type A (BOTOX and Dysport). Mov. Disord. (2004) 19(Suppl. 9):S68-S69. Abstract P158.
   PubMed Web of Science ®Google Scholar
• TANG X, WAN X: Comparison of Botox with a Chinese type A botulinum toxin. Chin. Med. J. (2000) 113(9):794-798.
   PubMed Web of Science ®Google Scholar
• RIEDER CR, SCHESTATSKY P, SOCAL MP et al.: A double-blind, randomized, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm. Clin. Neuropharmacol. (2007) 30(1):39-42.
   PubMed Web of Science ®Google Scholar
• JOST WH, KOHL A, BRINKMANN S, COMES G: Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX®) in healthy volunteers. J. Neural. Transm. (2005) 112:905-913.
   PubMed Web of Science ®Google Scholar
• ROGGENKÄMPER P, JOST WH, BIHARI K, COMES G, GRAFE S; FOR THE NT 201 BLEPHAROSPASM STUDY TEAM: Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J. Neural. Transm. (2006) 113(3):303-312.
   PubMed Web of Science ®Google Scholar
• BENECKE R, JOST WH, KANOVSKY P, RUZICKA E, COMES G, GRAFE S: A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology (2005) 64(11):1949-1951.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS A: Botulinum toxin type A: history and current cosmetic use in the upper face. Dis. Mon. (2002) 48(5):299-322.
   PubMed Web of Science ®Google Scholar
• AOKI KR: A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon (2001) 39(12):1815-1820.
   PubMed Web of Science ®Google Scholar
• AOKI KR: Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon (2002) 40(7):923-928.
   PubMed Web of Science ®Google Scholar
• AOKI R, FRANCIS J, REYNOLDS H, LEUMER D: Comparison of the therapeutic windows of different botulinum neurotoxin preparations in an animal model. Neurology (2003) 60(Suppl. 1):A213. Abstract P03.088.
   PubMedGoogle Scholar
• AOKI KR, SATORIUS A, ARDILA C, BROWN M, NICHOLSON G, FRANCIS J: Pharmacology of BOTOX®, Dysport®, Myobloc™ and BTX-A in animal models of efficacy and safety. 5th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Denver (CA) USA (23 – 25 June 2005) Poster 51.
   Google Scholar
• TRINDADE DE ALMEIDA A, MARQUES E, DE ALMEIDA J, CUNHA T, BORASO R: Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol. Surg. (2007) 33:S37-S43.
   Google Scholar
• LUC LJ, SERVANT JJ, JOUVE E: Botulinum toxin A: a 9-month clinical and 3D in vivo profilometric crow’s feet wrinkle formation study. J. Cosmet. Laser Ther. (2004) 6(1):16-20.
   PubMedGoogle Scholar
• ASCHER B, ZAKINE B, KESTEMONT P, BASPEYRAS M, BOUGARA A, SANTINI J: A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J. Am. Acad. Dermatol. (2004) 51(2):223-233.
   PubMed Web of Science ®Google Scholar
• MONHEIT G, CARRUTHERS A, BRANDT F, RAND R: A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol. Surg. (2007) 33:S51-S59.
   PubMedGoogle Scholar
• LEW H, YUN YS, LEE SY, KIM SJ: Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica (2002) 216(1):50-54.
   PubMed Web of Science ®Google Scholar
• KANE MA: The effect of botulinum toxin injections on the nasolabial fold. Plast. Reconstr. Surg. (2003) 112(5 Suppl.):66S-72S; discussion 73S-74S.
   Google Scholar
• PATEL MP, TALMOR M, NOLAN WB: Botox and collagen for glabellar furrows: advantages of combination therapy. Ann. Plast. Surg. (2004) 52(5):442-447.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS J, CARRUTHERS A: A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol. Surg. (2003) 29(8):802-809.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI PS, LASK G, LOWE NJ: Botulinum toxin type A gives adjunctive benefit to periorbital laser resurfacing. J. Cosmet. Laser Ther. (2004) 6(3):145-148.
   PubMedGoogle Scholar
• CARRUTHERS J, CARRUTHERS A: The effect of full-face broadband light treatments alone and in combination with bilateral crow's feet botulinum toxin type A chemodenervation. Dermatol. Surg. (2004) 30(3):355-366.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS J, CARRUTHERS A: The adjunctive use of botulinum toxin. Dermatol. Surg. (1998) 24(11):1244-1247.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS JA, LOWE NJ, MENTER MA et al.; FOR THE BOTOX GLABELLAR LINES I STUDY GROUP: A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J. Am. Acad. Dermatol. (2002) 46(6):840-849.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS JD, LOWE NJ, MENTER MA, GIBSON J, EADIE N; FOR THE BOTOX GLABELLAR LINES II STUDY GROUP: Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast. Reconstr. Surg. (2003) 112(4):1089-1098.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS A, CARRUTHERS J, LOWE NJ et al.; FOR THE Botox® GLABELLAR LINES I & II STUDY GROUPS: One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J. Clin. Res. (2004) 7:1-20.
   Google Scholar
• CARRUTHERS A, CARRUTHERS J, SAID S: Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol. Surg. (2005) 31(4):414-422.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS A, CARRUTHERS J: Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol. Surg. (2005) 31(10):1297-1303.
   PubMed Web of Science ®Google Scholar
• LOWE NJ, ASCHER B, HECKMANN M, KUMAR C, FRACZEK S, EADIE N; FOR THE BOTOX FACIAL AESTHETICS STUDY TEAM: Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol. Surg. (2005) 31(3):257-262.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS A, CARRUTHERS J, COHEN J: A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. Dermatol. Surg. (2003) 29(5):461-467.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS A, CARRUTHERS J: Long-term safety review of subjects treated with botulinum toxin type A for cosmetic use. American Academy of Dermatology Meeting. New York (NY) USA (28 July – 1 August 2004) Poster.
   Google Scholar
• RZANY B, DILL-MULLER D, GRABLOWITZ D, HECKMANN M, CAIRD D; GERMAN-AUSTRIAN RETROSPECTIVE STUDY GROUP: Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol. Surg. (2007) 33:S18-S25.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J, VUONG KD, AHSAN J: Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology (2003) 60(7):1186-1188.
   PubMed Web of Science ®Google Scholar
• DRESSLER D: Complete secondary botulinum toxin therapy failure in blepharospasm. J. Neurol. (2000) 247(10):809-810.
   PubMed Web of Science ®Google Scholar
• DRESSLER D, HALLETT M: Immunological aspects of Botox©, Dysport©, and Myobloc™/Neurobloc©. Eur. J. Neurol. (2006) 13(Suppl. 1):11-15.
   PubMed Web of Science ®Google Scholar
• LEE SK: Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol. Surg. (2007) 33:S105-S110.
   Google Scholar
• BINDER WJ: Long-term effects of botulinum toxin type A (Botox) on facial lines. Arch. Facial Plast. Surg. (2006) 8:426-431.
   PubMedGoogle Scholar
• FINZI E, WASSERMAN E: Treatment of depression with botulinum toxin A: a case series. Dermatol. Surg. (2006) 32(5):645-649; discussion 649-650.
   PubMed Web of Science ®Google Scholar
• RZANY B, ASCHER B, FRATILA A, MONHEIT GD, TALARICO S, STERRY W: Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch. Dermatol. (2006) 142(3):320-326.
   PubMedGoogle Scholar
• FLYNN TC, CARRUTHERS JA, CARRUTHERS JA, CLARK RE II: Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study. Dermatol. Surg. (2003) 29(9):943-950; discussion 950-951.
   PubMed Web of Science ®Google Scholar
• FLYNN TC, CARRUTHERS JA, CARRUTHERS JA: Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol. Surg. (2001) 27(8):703-708.
   PubMed Web of Science ®Google Scholar
• CARRUTHERS J, CARRUTHERS A: Botulinum toxin A in the mid and lower face and neck. Dermatol. Clin. (2004) 22(2):151-158.
   PubMed Web of Science ®Google Scholar
• KANE MA: Nonsurgical treatment of platysmal bands with injection of botulinum toxin A revisited. Plast. Reconstr. Surg. (2003) 112(5 Suppl.):125S-126S.
   PubMedGoogle Scholar
• BEER K, YOHN M, CLOSTER J: A double-blinded, placebo-controlled study of Botox® for the treatment of subjects with chin rhytids. J. Drugs Dermatol. (2005) 4(4):417-422.
   PubMedGoogle Scholar
• AHN J, HORN C, BLITZER A: Botulinum toxin for masseter reduction in Asian patients. Arch. Facial Plast. Surg. (2004) 6(3):188-191.
   PubMedGoogle Scholar
• PARK MY, AHN KY, JUNG DS: Application of botulinum toxin A for contouring of the lower face. Dermatol. Surg. (2003) 29(5):477-483.
   PubMed Web of Science ®Google Scholar
• KANE MA: Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast. Reconstr. Surg. (1999) 103(2):656-663; discussion 664-665.
   PubMed Web of Science ®Google Scholar